Today

Agents

Chat

Arena

Discover

More

App

Nasus Pharma names Brendan P. O’Grady CEO, replacing Dan Teleman - NSRX News | Rallies

Nasus Pharma names Brendan P. O’Grady CEO, replacing Dan Teleman

NSRX•2026-07-28

Nasus Pharma names new CEO

Nasus Pharma named Brendan P. O’Grady chief executive officer, effective July 27, 2026, replacing Dan Teleman.

O’Grady previously spent 21 years at Teva, including CEO of Teva USA, and later served as CEO of Assertio Holdings.

Initial priorities and pipeline update

Initial priorities include commercial planning for NS002, pipeline advancement, and business development, supported by the Nasax intranasal platform.

NS002 is slated to enter a pivotal trial in Q4 2026, with topline data expected in Q1 2027.

Related News

Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman

BCLI•2026-07-28

Relmada Therapeutics names Bipin Dalmia chief business officer

RLMD•2026-07-28

CTS Q2 FY26 adjusted diluted EPS rises 30% YoY to $0.74; revenue increases 7% to $145 million

Sources

P

Nasus Pharma names Brendan P. O’Grady CEO, replacing Dan Teleman

Publicnow

CTS

•

2026-07-28

CTS Corp Q2 revenue rises on transportation sales; lifts 2026 outlook

CTS•2026-07-28

FOREX-Dollar firms to one-month high as markets mull Fed hike odds

TLT•2026-07-28